Monday, July 1, 2024 NIH-Sponsored Trial of Nasal COVID-19 Vaccine Opens Colorized scanning electron micrograph of a cell (blue) infected with the Omicron strain of SARS-CoV-2 virus particles (pink), isolated from a patient sample. Credit: NIAID A Phase 1 trial of an experimental nasal COVID-19 vaccine is now enrolling healthy adults at three sites in the United States. This is the first time that the vaccine, which was designed and tested in pre-clinical studies by scientists from NIH's National Institute of Allergy and Infectious Diseases (NIAID), is being tested in people. The candidate vaccine could provide enhanced breadth of protection against emerging virus variants.    National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period.  This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107